• Liquidia posted Q1 net income of $52.9 million, swinging from a net loss of $38.4 million a year earlier; diluted EPS was $0.52.
• Net sales were $129.9 million, compared with no net sales a year earlier, as YUTREPIA shipments began in June 2025 following full FDA approval on May 23, 2025.
• Cash and cash equivalents climbed to $222.8 million as of March 31 from $190.7 million as of Dec. 31.
• YUTREPIA net product sales were about $130 million, with more than 4,500 unique prescriptions and about 3,750 patients started on treatment since launch in June 2025 through April 30, 2026.
• Roger Jeffs said uptake remained strong in PAH and PH-ILD; Liquidia is screening PH-ILD patients in a Phase 4 Tyvaso and Tyvaso DPI transition study and in the Phase 3 Re-Spire study of L606.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110630PRIMZONEFULLFEED9717084) on May 11, 2026, and is solely responsible for the information contained therein.